These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 29460705)

  • 1. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
    Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
    J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER; Murillo JR; Putney D; Hobaugh EC
    J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
    Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
    J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
    Ihaddadene R; Le Gal G; Delluc A; Carrier M
    Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
    Li A; Garcia DA; Lyman GH; Carrier M
    Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].
    Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP
    Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
    Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
    Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
    Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
    Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
    Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
    Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies.
    Wang TF; Hill M; Mallick R; Chaudry H; Unachukwu U; Delluc A; Carrier M
    Thromb Res; 2023 Nov; 231():128-134. PubMed ID: 37857226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Treatment of Venous Thromboembolism in Patients with Cancer.
    Prandoni P
    Adv Exp Med Biol; 2017; 906():123-135. PubMed ID: 27620308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.